Extended-release topiramate capsules
First Claim
Patent Images
1. A container comprising an extended-release topiramate capsule and desiccant, wherein the extended-release topiramate capsule comprises:
- a capsule shell comprising a single population of coated particles;
wherein each coated particle comprises a core and a coating thereon;
wherein each particle core comprises a homogeneous mixture throughout its core, the mixture comprising;
topiramate;
one or more filler(s); and
one or more binder(s);
wherein the coating comprises;
one or more release controlling agent(s);
one or more pore former(s); and
one or more plasticizer(s);
wherein the components in the particle core and coating are present in amounts that provide extended release of topiramate; and
wherein, when a single dose is given to a healthy human subject, an AUC0-inf of 170 to 210 h·
μ
g/mL within a 95% confidence interval, and a Cmax of 2 to 4 μ
g/mL within a 95% confidence interval are achieved in the subject'"'"'s plasma.
2 Assignments
0 Petitions
Accused Products
Abstract
An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s).
-
Citations
11 Claims
-
1. A container comprising an extended-release topiramate capsule and desiccant, wherein the extended-release topiramate capsule comprises:
-
a capsule shell comprising a single population of coated particles; wherein each coated particle comprises a core and a coating thereon; wherein each particle core comprises a homogeneous mixture throughout its core, the mixture comprising; topiramate; one or more filler(s); and one or more binder(s); wherein the coating comprises; one or more release controlling agent(s); one or more pore former(s); and one or more plasticizer(s); wherein the components in the particle core and coating are present in amounts that provide extended release of topiramate; and wherein, when a single dose is given to a healthy human subject, an AUC0-inf of 170 to 210 h·
μ
g/mL within a 95% confidence interval, and a Cmax of 2 to 4 μ
g/mL within a 95% confidence interval are achieved in the subject'"'"'s plasma. - View Dependent Claims (2, 3, 4)
-
-
5. A container comprising an extended-release topiramate capsule and desiccant, wherein the extended-release topiramate capsule comprises:
-
a capsule shell comprising a single population of coated particles; wherein each coated particle comprises a core and a coating thereon; wherein each particle core comprises a homogeneous mixture throughout its core, the mixture comprising; 40 wt-% to 50 wt-% of topiramate, based on the total weight of an uncoated particle core; 45 wt-% to 55 wt-% of one or more filler(s), based on the total weight of an uncoated particle core; and 3 wt-% to 7 wt-% of one or more binder(s), based on the total weight of an uncoated particle core; wherein the coating comprises; 55 wt-% to 65 wt-% of one or more release control agent(s), based on the total weight of the coating; 20 wt-% to 25 wt-% of one or more pore former(s), based on the total weight of the coating; and 10 wt-% to 20 wt-% of one or more plasticizer(s), based on the total weight of the coating; wherein the particles are coated in an amount sufficient to provide a weight gain of 8% to 14%. - View Dependent Claims (6, 7, 8, 9, 10, 11)
-
Specification